Entering text into the input field will update the search result below

Bristol-Myers transfers Erbitux to Eli Lilly in North America

Apr. 16, 2015 12:53 PM ETBristol-Myers Squibb Company (BMY) StockBMY, LLYBy: Douglas W. House, SA News Editor
  • Bristol-Myers Squibb (BMY +0.1%) and Eli Lilly (LLY -0.2%) agree to transfer the North American rights to Erbitux (cetuximab) from BMY to Lilly. The transition, including commercialization and manufacturing responsibilities, should be completed in Q4.
  • Erbitux is approved for the treatment of certain head and neck and colorectal cancers. It was developed by ImClone Systems which Lilly acquired for $6.5B in 2008. ImClone and BMY entered into a co-development and co-promotion agreement covering the territory of North America in 2007. It generated $723M in sales for BMY the past four quarters.

Recommended For You

More Trending News

About BMY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BMY--
Bristol-Myers Squibb Company